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Abstract
Background: I have postulated that arachidonic acid release from rat liver cells is associated with
cancer chemoprevention. Since it has been reported that inhibition of proteasome activities may
prevent cancer, the effects of proteasome inhibitors on arachidonic acid release from cells and on
prostaglandin I2 production in rat liver cells were studied.
Results:  The proteasome inhibitors, epoxomicin, lactacystin and carbobenzoxy-leucyl-leucyl-
leucinal, stimulate the release of arachidonic acid from rat glial, human colon carcinoma, human
breast carcinoma and the rat liver cells. They also stimulate basal and induced prostacycin
production in the rat liver cells. The stimulated arachidonic acid release and basal prostaglandin I2
production in rat liver cells is inhibited by actinomycin D.
Conclusions: Stimulation of arachidonic acid release and arachidonic acid metabolism may be
associated with some of the biologic effects observed after proteasome inhibition, e.g. prevention
of tumor growth, induction of apoptosis, stimulation of bone formation.
Background
The proteasome degrades many cellular proteins, several
with regulatory functions. It is not surprising that protea-
some inhibitors affect many biologic processes [1] includ-
ing prevention of cancer [2]. The effect of proteasome
inhibition on cell growth and possible cancer chemopre-
vention has been reviewed by Adams [3].
Epoxomicin, an α'-β'-epoxyketone, appears to be the most
selective proteasome inhibitor. Based on its anti-tumor
activity, this product was originally isolated from an actin-
omycetes strain C-996-17 [4]. It inhibits the chymot-
rypsin-like activity (cleavage after large hydrophobic
residues), trypsin-like activity (cleavage after basic resi-
dues) and peptidyl-glutamyl peptide hydrolyzing (PGPH)
activity (cleavage after acidic residues) of proteasomes.
Activities of the Ca++-dependent proteases, calpain,
papain, chymotrypsin, trypsin and cathepsin are not
affected by epoxomicin even at a 50 µM concentration [5].
The β-lactone, lactacystin, is relatively selective but can
inhibit cathepsin A [6]. Peptide aldehydes, in addition to
inhibiting proteasome activity, can also inhibit lysosomal
and Ca++-activated proteases [7]. The peptides containing
the carboxyvinylsulfone moiety inhibit cysteine proteases
[8,9].
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I have shown that inhibition of proteolysis by phenyl-
methylsulphonyl fluoride, the peptide aldehydes car-
bobenzoxy-leucyl-leucyl-norvalinal and carbobenzoxy-
leucyl-leucyl-leucinal (ZLLL) and lactacystin stimulate
induced prostaglandin (PGI2) production in rat liver cells
[10,11]. Lactacystin stimulates arachidonic acid (AA)
release from these cells [11]. Others have reported that
proteasome inhibition up-regulates cyclooxygenase-2
(COX-2) and stimulates PGE2 production in neuronal
cells [12].
In this report, evidence is presented that proteasome
inhibitors stimulate PGI2 production by rat liver cells as
well as the release of AA from rat liver, rat glial, human
colon carcinoma and human breast carcinoma cells in
culture. The stimulation of AA release from rat liver cells
is partially inhibited by preincubation of the cells with
actinomycin D.
Results and Discussion
Of the cells examined (C-9 rat liver, C-6 rat glial, HT-29
human colon carcinoma and BT-20 human breast carci-
noma) the prostanoid metabolic profile has been
described only for C-9 rat liver cells (95% is PGI2 and less
than 5% is PGE2 and PGF2α) [13]. At the low cell densities
used in this study, only PGI2, the main product of COX-
mediated synthesis, can be quantitatively estimated. The
rat liver cells express COX-2 both constitutively and after
induction [14]. The effect of time on basal and 12-0-tetra-
decanoylphorbol-13-acetate (TPA) induced PGI2 synthe-
sis during incubation of cells with epoxomicin is shown in
Fig. 1.
The stimulation of basal PGI2 production by epoxomicin
and TPA-induced PGI2 production by epoxomicin and
lactacystin as a function of dose is shown in Fig. 2. As little
as 0.3 µM epoxomicin stimulates TPA-induced PGI2 pro-
duction significantly (Fig. 2-B). It is 10 to 15 times more
effective than lactacystin (compare Fig. 2-B and 2-C).
Using purified bovine erythrocyte proteasomes, epox-
omicin inhibits the chymotrypsin-like activity, about 4 to
5 times more effectively than does clasto-lactacystin β-lac-
tone, the derivative of lactacystin [5]. They are almost
equally effective on inhibiting the trypsin-like and PGPH-
like activities [5]. Assuming that epoxomicin and lactacys-
tin have equal access to the proteasome and that proteas-
ome activity is regulating COX-2 in rat liver cells similarly
to neuronal cells [12] then COX-2 may be degraded in the
proteasome by cleavage after large hydrophobic residues.
The amplification of PGI2 production (Figs. 1 and 2) after
inhibition by epoxomicin could reflect not only stabiliza-
tion of COX-2 but also an intracellular increase in the con-
centration of the substrate i.e. the AA that is produced
during hydrolysis of the membrane phopholipids by
PLase activity [15]. Extracellular and/or intracellular
release of AA will depend, in part, on the localization of
the phospholipids in the membrane, e.g. in its inner or
outer leaflet [16]. Release of AA in response to several ago-
nists has been described [17-20].
The effect of a 2, 4 or 6-h incubation on AA release from
rat liver and rat glial cells by 1.0 µM epoxomicin was
determined. Only after the 6-h incubation were the differ-
ences significant statistically. Regulation of PLase activity
by the proteasome pathway appears to be a relatively slow
Time-course of (A) basal and (B) TPA-induced 6-keto-PGF1α  production during incubation with 1.2 µM epoxomicin Figure 1
Time-course of (A) basal and (B) TPA-induced 6-keto-PGF1α 
production during incubation with 1.2 µM epoxomicin. In (B) 
16.7 nM TPA was used. Analyses were performed with dupli-
cate and triplicate dishes. Mean values are shown.BMC Pharmacology 2004, 4:15 http://www.biomedcentral.com/1471-2210/4/15
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Effect of epoxomicin on (A) basal and (B) TPA-induced 6-ketoPGF1α production and (C) effect of lactacystin on TPA-induced 6- ketoPGF1α production Figure 2
Effect of epoxomicin on (A) basal and (B) TPA-induced 6-ketoPGF1α production and (C) effect of lactacystin on TPA-induced 6-
ketoPGF1α production. Cells were incubated with the reagents for 6 hours. The analyses were performed with triplicate dishes 
*- statistically significant vs MEM/BSA. **- Statistically significant vs TPA.
Dose-response of epoxomicin, lactacystin and ZLLL on AA release from rat liver cells Figure 3
Dose-response of epoxomicin, lactacystin and ZLLL on AA release from rat liver cells. After incubation for 6 hours. The anal-
yses were performed with triplicate dishes. *- Statistically significant vs MEM/BSA.BMC Pharmacology 2004, 4:15 http://www.biomedcentral.com/1471-2210/4/15
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process. After a 6-h incubation, epoxomicin, lactacystin
and ZLLL stimulate the release of extracellular AA from rat
liver cells (Fig. 3) and AA release after TPA-induction
(3.7% vs 13.5% in the presence of 1.0 µM epoxomicin).
Epoxomicin also stimulates the release of AA from rat
glial, human colon carcinoma and human breast carci-
noma cells (Table 1). The stimulation of AA release from
the rat liver cells after incubation with epoxomicin is par-
tially inhibited by pre-incubation of the cells for 2-h with
actinomycin (Fig. 4) suggesting that a fraction of the PLase
is induced. As expected, the inhibition of TPA-induced
PGI2 production by actinomycin D is complete (Fig. 5).
Thus, some mechanisms leading to maximum AA release
appear to be genomic. The induced PLase activity, proba-
bly PLA2, could reflect expression of either a secretory or
cytosolic PLA2 or some combination of both enzymes
[21].
The release of AA from rat liver cells, most likely resulting
from PLase activation, is associated with cancer chemo-
prevention [14,17-19], [22-24]. In addition to its intrinsic
biologic activities, AA regulates production of lipoxygen-
Table 1: Effect of Epoxomicin on AA Release from Rat Glial, 
Human Colon Carcinoma and Human Breast Carcinoma Cells.
Cell Type % AA Release
MEM/BSA control With epoxomicin
Rat glial (C-6) 9.0 ± 0.07 11.4 ± 0.28
Human Colon Carcinoma 
(HT-29)
7.8 ± 0.05 9.4 ± 0.33
Human Breast Carcinoma 
(BT-20)
12.1 ± 0.35 14.2 ± 0.31
Cells were incubated in the presence and absence of 4.5 µM 
epoxomicin for 6-h, 12-h or 9-h (C-6, HT-29, BT-20 respectively). 
Analyses were performed with quadruplicate (C-6 and HT-29) or 
quintuplicate (BT-20) dishes. All values are expressed as Mean ± SE (n 
= 4 or n = 5). All data with epoxomicin are statistically significant vs 
MEM/BSA.
Effect of Actinomycin D on AA release from rat liver cells Figure 4
Effect of Actinomycin D on AA release from rat liver cells. 
Cells were preincubated with and without 1.0 µM actinomy-
cin D for 2-h, then incubated in the presence and absence of 
epoxomicin and actinomycin D for another 6-h. The analyses 
were performed with triplicate or quadruplicate dishes. *- 
Statistically significant vs epoxomicin in the presence of actin-
omycin D.
Effects of actinomycin D on TPA-induced 6-Keto-PGF1α pro- duction Figure 5
Effects of actinomycin D on TPA-induced 6-Keto-PGF1α pro-
duction. Cells were preincubated with 1.0 µM actinomycin D 
for 2-h and then incubated in the presence and absence of 
0.6 µM epoxomicin and/or 16.7 µM TPA for another 6-h. 
The analyses were performed with triplicate dishes. *- Statis-
tically significant vs TPA in the absence of actinomycin D. **- 
Statistically significant vs epoxomicin plus TPA in the absence 
of actinomycin D.BMC Pharmacology 2004, 4:15 http://www.biomedcentral.com/1471-2210/4/15
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ase, cytochrome P-450, and epoxygenase products as well
as COX activities. Prostanoid profiles differ with cell type
and individual AA metabolites have different pharmaco-
logical properties [15]. COX-2 activity, as measured by
PGI2 production, is stimulated by proteasome inhibition
(Fig. 1 and 2). Thus, some biologic effects of proteasome
inhibition, e.g. stimulation of bone formation [25], may
reflect the metabolism of the intracellular AA.
Inhibition of COX-2 activity is one possible mechanism
that has been proposed to prevent colon cancer [26].
However, rather than inhibiting, tamoxifen and
raloxifene, statins and epoxomicin stimulate COX-2 activ-
ity and AA release from rat liver cells [14,17-19]. As shown
in Table 1, epoxomicin stimulates AA release from human
colon carcinoma, breast carcinoma and rat glial cells.
Tamoxifen and simvastatin also stimulate AA release from
the human colon carcinoma and human breast carcinoma
cells (unpublished data). These drugs have been reported
to prevent cancer [27,28]. At least as measured by the COX
activity of rat liver cells, tamoxifen, raloxifene, statins and
proteasome inhibitors could be preventing cancer by a
COX independent mechanism.
AA resulting from proteasome inhibition has many intrin-
sic biologic properties [reviewed in [29]]. Some of these
activities may trigger PLase activity. The causal relation-
ship of AA to cancer prevention (if any) is unclear. Pro-
duction of AA by the tumor-suppressive type-II
phospholipase A2 (PLA2G2A) may be related to the cancer
prevention [22-24]. It is not surprising that control of
PLase activities present an attractive area for cancer pre-
vention studies [30].
Methods
The rat liver (C-9 cell line) and human breast carcinoma
(the BT-20 cell line) were purchased from the American
Type Culture Collection (Manassas, VA, USA). The rat
liver glial cells (C-6 cell line) was obtained from Dr. Elaine
Lai of the Department of Biology, Brandeis University and
the human colon carcinoma (the HT-29 cell line) was
obtained from Dr. Basil Rigas, American Health Founda-
tion, Valhalla, NY, USA. They were maintained in Eagle's
minimum essential medium (MEM) supplemented with
10% fetal bovine serum. [3H] AA (91.8 Ci/mmol) was
obtained from NEN Life Science Products, Inc. (Boston,
MA, USA). Epoxomicin, lactacystin and ZLLL were pur-
chased from Biomol (Plymouth Meeting, PA, USA). All
other reagents were from Sigma Chemical Co. (St. Louis,
MO, USA). Rat liver cells incubating with lactacystin (5.4
µM) or ZLLL (1.0 µM) for 6-h have been tested for viabil-
ity by a tetrazolium-based assay and found not to be toxic
[31].
Two days prior to experiments, the rat liver cells were
treated with 0.25% trypsin-EDTA and, after addition of
minimal essential media (MEM) containing 10% fetal calf
serum, the floating cells were seeded onto 35 mm culture
dishes. The plating densities varied from 0.1 to 0.5 × 105
cells/35 mm dish. The freshly seeded cultures were incu-
bated for 24-h to allow for cell attachment. After decanta-
tion of MEM containing the fetal bovine serum, 1.0 ml
fresh MEM containing 10% fetal bovine serum and [3H]
AA (0.2 µCi/ml) were added and the cells incubated for
another 24-h. The cells were washed 4 times with MEM
and incubated for various periods of time with 1.0 ml of
MEM containing 1.0 mg BSA/ml (MEM/BSA) and differ-
ent concentrations of each compound. The culture fluids
were then decanted, centrifuged at 2000 × g for 10 min,
and 200 µl of the supernate counted for radioactivity.
Radioactivity recovered in the washes before the
incubation was compared to input radioactivity to calcu-
late the % radioactivity incorporated into the cells [31].
For PGI2 production, 1.0 ml of MEM supplemented with
10% fetal bovine serum, void of [3H]AA, was added after
the first 24-h incubation. The cells were incubated for
another 24-h, washed three times with MEM, then incu-
bated with the compounds in MEM/BSA for various peri-
ods of time. The culture fluids were decanted and
analyzed for 6-keto-PGF1α, the stable hydrolytic product
of PGI2, by radioimmunoassay [32].
The [3H] AA release is presented as a percentage of the
radioactivity incorporated by the cells. Except for the time-
course experiments which used duplicate dishes, three to
five culture dishes were used for each experimental point.
The data are expressed as mean values ± SEM. The data
were evaluated statistically by the unpaired Student's t-test.
A P value < 0.05 was considered significant.
Acknowledgements
My thanks to Hilda B. Gjika for preparation of the manuscript and to Dr. 
Armen H. Tashjian, Jr., Department of Genetic and Complex Diseases, 
Harvard School of Public Health, for his continuing interest in these studies.
References
1. Kisselev AF, Goldberg AL: Proteasome inhibitors: from
research tools to drug candidates. Chem Biol 2001, 8:739-758.
2. Mitchell BS: The proteasome – an emerging therapeutic tar-
get in cancer. N Engl J Med 2003, 348:2597-2598.
3. Adams J: Potential for proteasome inhibition in the treatment
of cancer. Drug Discov Today 2003, 8:307-315.
4. Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K,
Yamamoto H, Konishi M, Oki T: Epoxomicin, a new antitumor
agent of microbial origin. J Antibiot (Tokyo 1992, 45:1746-1752.
5. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epox-
omicin, a potent and selective proteasome inhibitor, exhibits
in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 1999,
96:10403-10408.
6. Ostrowska H, Wojcik C, Omura S, Worowski K: Lactacystin, a
specific inhibitor of the proteasome, inhibits human platelet
lysosomal cathepsin A-like enzyme.  Biochem Biophys Res
Commun 1997, 234:729-732.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pharmacology 2004, 4:15 http://www.biomedcentral.com/1471-2210/4/15
Page 6 of 6
(page number not for citation purposes)
7. Mellgren RL: Specificities of cell permeant peptidyl inhibitors
for the proteinase activities of mu-calpain and the 20 S
proteasome. J Biol Chem 1997, 272:29899-29903.
8. Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL,
Ploegh H: Covalent modification of the active site threonine
of proteasomal beta subunits and the Escherichia coli
homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U
S A 1997, 94:6629-6634.
9. Bromme D, Klaus JL, Okamoto K, Rasnick D, Palmer JT: Peptidyl
vinyl sulphones: a new class of potent and selective cysteine
protease inhibitors: S2P2 specificity of human cathepsin O2
in comparison with cathepsins S and L.  Biochem J 1996,
315:85-89.
10. Levine L: Proteolysis negatively regulates agonist-stimulated
arachidonic acid metabolism. Cell Signal 1998, 10:653-659.
11. Levine L: Lactacystin stimulates arachidonic acid metabolism
in rat liver cells: effects of cell density on arachidonic acid
release, PGI2 production and cyclooxygenase activity. Pros-
taglandins Leukot Essent Fatty Acids 2000, 63:371-375.
12. Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME: Proteas-
ome inhibition in neuronal cells induces a proinflammatory
response manifested by upregulation of cyclooxygenase-2,
its accumulation as ubiquitin conjugates, and production of
the prostaglandin PGE(2).  Arch Biochem Biophys 2000,
374:325-333.
13. Rigas A, Levine L: Arachidonic acid metabolism by rat liver
cells (the C-9 cell line). J Pharmacol Exp Ther 1984, 231:230-235.
14. Levine L: Tamoxifen and the raloxifene analog LY117018:
their effects on arachidonic acid release from cell in culture
and on prostaglandin I2 production by rat liver cells. BMC
Cancer 2004.
15. Smith WL: The eicosanoids and their biochemical mecha-
nisms of action. Biochem J 1989, 259:315-324.
16. Edidin M: The state of lipid rafts: from model membranes to
cells. Annu Rev Biophys Biomol Struct 2003, 32:257-279.
17. Levine L: Does the release of arachidonic acid from cells play
a role in cancer chemoprevention? FASEB J 2003, 17:800-802.
18. Levine L: Tamoxifen stimulates arachidonic acid release from
rat liver cells by an estrogen receptor-independent, non-
genomic mechanism. BMC Cancer 2003, 3:24.
19. Levine L: Statins stimulate arachidonic acid release and pros-
taglandin I2 production in rat liver cells. Lipids Health Dis 2003,
2:1.
20. Levine L: Nuclear receptor agonists stimulate release of ara-
chidonic acid from rat liver cells. Prostaglandins Leukot Essent Fatty
Acids 2002, 67:453-459.
21. Diaz BL, Arm JP: Phospholipase A(2). Prostaglandins Leukot Essent
Fatty Acids 2003, 69:87-97.
22. Praml C, Amler LC, Dihlmann S, Finke LH, Schlag P, Schwab M:
Secretory type II phospholipase A2 (PLA2G2A) expression
status in colorectal carcinoma derived cell lines and in nor-
mal colonic mucosa. Oncogene 1998, 17:2009-2012.
23. Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mul-
h e r k a r  R ,  D o v e  W F ,  L a n d e r  E S :  Secretory phospholipase
Pla2g2a confers resistance to intestinal tumorigenesis. Nature
Genetics 1997, 17:88-91.
24. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buch-
berg AM: The secretory phospholipase A2 gene is a candidate
for the Mom1 locus, a major modifier of ApcMin-induced
intestinal neoplasia. Cell 1995, 81:957-966.
25. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G,
Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR: Selec-
tive inhibitors of the osteoblast proteasome stimulate bone
formation in vivo and in vitro. J Clin Invest 2003, 111:1771-1782.
26. Subbaramaiah K, Dannenberg AJ: Cyclooxygenase 2: a molecular
target for cancer prevention and treatment. Trends Pharmacol
Sci 2003, 24:96-102.
27. Jordan VC, Morrow M: Tamoxifen, raloxifene, and the preven-
tion of breast cancer. Endocr Rev 1999, 20:253-278.
28. Brower V: Of cancer and cholesterol: studies elucidate anti-
cancer mechanisms of statins.  J Natl Cancer Inst 2003,
95:844-846.
29. Brash AR.: Arachidonic acid as a bioactive molecule. J Clin Invest
2001, 107:1339-1345.
30. Laye JP, Gill JH: Phospholipase A2 expression in tumours: a tar-
get for therapeutic intervention?  Drug Discov Today 2003,
8:710-716.
31. Levine L: Stimulated release of arachidonic acid from rat liver
cells by celecoxib and indomethacin. Prostaglandins Leukot Essent
Fatty Acids 2001, 65:31-35.
32. Levine L: Measurement of arachidonic acid metabolites by
radioimmunoassay. Manual of Clinical Laboratory Immunol-
ogy. 3rd edition. Edited by: Rose NR, Friedman H, Fahey JL. Wash-
ington DC: American Society for Microbiology; 1986:685-691. 